A multicenter randomized trial in Japan shows that real-time peripheral gaze guidance significantly improves adenoma detection rate (ADR) during colonoscopy — without increasing withdrawal time. In the EYE-SIGHT trial (n=400), patients were randomized to standard colonoscopy or an eye-tracking feedback (ETF) system that prompted endoscopists to scan the periphery of the monitor. Key Results Notably, detection improved for: Advanced adenoma detection and sessile serrated lesion detection did not significantly change.
Author: Abhay Panchal
In a landmark policy effort, the American College of Gastroenterology (ACG) published a modified Delphi consensus outlining how artificial intelligence should be responsibly integrated into GI, hepatology, and endoscopy practice. The paper — Artificial Intelligence for Gastroenterology Practice: A Modified Delphi Consensus — reflects input from 32 experts and 12 industry partners across endoscopy, clinical operations, IBD, liver disease, education, and ethics. What Reached Consensus Endoscopy Clinical Operations IBD & Liver Disease Training & Workforce Governance & Equity The Strategic Signal This is more than a technology endorsement — it is a governance framework. ACG positions AI as augmentative, not…
Basic science continued to advance gastroenterology and hepatology in 2025, offering new insights into disease mechanisms and revealing promising paths for future therapies. Last year’s most-read studies highlight how discoveries at the cellular and molecular level are shaping the way researchers and clinicians think about gut and liver health.
Miami-based startup Cervco has launched a $169 direct-to-consumer Gut-Brain Wellness Test, positioning it as the first at-home assay focused specifically on microbiome markers associated with cognitive wellness. The test analyzes four bacterial targets using digital droplet PCR (ddPCR): Users receive a Gut-Brain Wellness Score (0–100) alongside lifestyle assessments and suggested interventions. No prescription is required. Results are processed in CLIA-certified labs and returned in 2–3 weeks. The Science Signal — and the Caveat Cervco cites emerging research linking specific gut bacteria to pathways involved in inflammation, gut barrier integrity, and neurocognitive function. However: This places Cervco squarely within the rapidly…
The U.S. FDA has approved Optune Pax, a first-of-its-kind wearable device from Novocure, for use in combination with gemcitabine and nab-paclitaxel in patients with locally advanced pancreatic cancer. The system delivers tumor treating fields (TTFields) — low-intensity alternating electric fields that disrupt cancer cell division — through adhesive arrays worn on the abdomen and connected to a portable generator. Key Data: PANOVA-3 Trial There was no difference in progression-free survival, but the overall survival and pain control signals supported approval. Safety & Practical Considerations TTFields are already approved in glioblastoma, mesothelioma, and metastatic NSCLC. This marks the first new FDA…
ACG Secures Major Policy Wins on CRC Surveillance, Telehealth & PBM Reform The American College of Gastroenterology (ACG) announced key advocacy victories in the newly signed $1.2 trillion federal funding package — with meaningful implications for colorectal cancer screening, telehealth access, and drug pricing reform. 🔎 Surveillance Colonoscopy Recognized in Federal Report Language For the first time, Congressional appropriations language explicitly acknowledges the full colorectal cancer (CRC) screening continuum — including surveillance colonoscopy for patients with a history of polyps. The report urges CMS to reference U.S. Multi-Society Task Force recommendations and highlights rising early-onset CRC rates. While not statutory…
In a new policy paper published in Annals of Internal Medicine, the American College of Physicians (ACP) argues that the term “provider” is not merely imprecise — it is ethically consequential. Authored by Lois Snyder Sulmasy, JD, and Jan K. Carney, MD, MPH, on behalf of the ACP Ethics, Professionalism and Human Rights Committee, the paper contends that labeling physicians as “providers” contributes to the deprofessionalization of medicine in an era of commercialization and corporatization. Key arguments: ACP formally recommends: The broader signal:As healthcare becomes increasingly corporatized and technology-driven, language may be one of the last frontiers preserving professional identity…
Geneoscopy announced that the U.S. Patent Trial and Appeal Board (PTAB) invalidated all challenged claims of Exact Sciences’ ’746 patent — the second ruling in its favor after a prior decision invalidated claims in Exact’s ’781 patent. With both patents now invalidated at the PTAB level, Geneoscopy has effectively removed the patent claims asserted against its RNA-based colorectal cancer screening test, ColoSense®, in ongoing litigation. The ruling strengthens Geneoscopy’s position as it commercializes ColoSense, an FDA-approved stool-based RNA test for average-risk adults aged 45+. Strategic implications: The broader takeaway: the battle in stool-based colorectal cancer screening is shifting from patent…
Artificial intelligence is no longer a side conversation in gastroenterology. It is moving to the center of operations — and future competitive advantage. In this episode of The Scope Forward Show, I sit down with Dr. Michael Dragutsky (Chairman, One GI), Christa Newton (CEO, One GI), Aniket Behera (COO and Co-founder, 100ms), and Satish Malnaik (CEO, NextServices). We go inside One GI’s AI strategy — not to debate AI — but to examine what happens when a PE-funded scaled GI platform treats AI as a leadership decision. This is not about implementing AI in the endoscopy room. It’s not about bounding boxes in CADe or CADx. AI is about the business model of…
In a move that may preview the next phase of surgical care delivery, Oath Surgical has partnered with NVIDIA to build AI-native ambulatory surgery centers (ASCs) powered by real-time, multimodal intelligence. Oath is developing OathOS, a software-defined operating layer that integrates with existing OR infrastructure — including video, imaging, robotics, and device systems — transforming outpatient surgical centers into continuously sensing, AI-enabled environments. Rather than rebuilding facilities, Oath focuses on upgrading the installed base of ASCs, allowing centers to: NVIDIA’s role extends beyond dashboards and analytics. The collaboration centers on what NVIDIA calls “physical AI” — embedding AI directly into…